Compare TPCS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPCS | MDCX |
|---|---|---|
| Founded | 1956 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 10.9M |
| IPO Year | 2008 | 2025 |
| Metric | TPCS | MDCX |
|---|---|---|
| Price | $5.10 | $0.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 21.0K | ★ 5.7M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,644,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.88 | $0.14 |
| 52 Week High | $6.31 | $2.78 |
| Indicator | TPCS | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 34.77 |
| Support Level | $5.12 | $0.15 |
| Resistance Level | $5.69 | $0.19 |
| Average True Range (ATR) | 0.14 | 0.01 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 11.04 | 37.21 |
Techprecision Corp manufactures precision, large-scale fabricated and machined metal structural components and systems. The company provides end-to-end services, transforming raw materials into precision finished products through custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation, and testing. It manufactures products in accordance with customers' drawings and specifications while complying with applicable national and international industry codes and standards. Its segments are: Ranor, which generates the majority of revenue, and Stadco, both focused on the manufacture and assembly of components mainly for defense and other precision industrial customers.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.